Rocket Pharmaceuticals Stock Surges 34% on FDA Alignment for Danon Disease Treatment
12 Setembro 2023 - 6:28PM
Dow Jones News
By Sabela Ojea
Shares of Rocket Pharmaceuticals surged 34% to $20.46 in
post-market trading on Tuesday after the company said it reached
alignment with the Food and Drug Administration regarding its Phase
2 trial for the treatment of Danon disease.
The Cranbury, N.J.-based pharmaceutical company said its study
would evaluate the use of the investigational gene therapy RP-A501
to treat 12 patients with Danon disease.
Danon is a rare genetic disorder that has no cure, and is known
for weakening the heart and movement muscles, as well as
intellectual disability.
The trial will support accelerated approval of Rocket's
treatment by the FDA.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
September 12, 2023 17:13 ET (21:13 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Rocket Pharmaceuticals (NASDAQ:RCKT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Rocket Pharmaceuticals (NASDAQ:RCKT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
